DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Da Hyun | ko |
dc.contributor.author | Park, Cheol-Kyu | ko |
dc.contributor.author | Chung, Chaeuk | ko |
dc.contributor.author | Oh, In-Jae | ko |
dc.contributor.author | Kim, Young-Chul | ko |
dc.contributor.author | Park, Dongil | ko |
dc.contributor.author | Kim, Jinhyun | ko |
dc.contributor.author | Kwon, Gye Cheol | ko |
dc.contributor.author | Kwon, Insun | ko |
dc.contributor.author | Sun, Pureum | ko |
dc.contributor.author | Shin, Eui-Cheol | ko |
dc.contributor.author | Lee, Jeong Eun | ko |
dc.date.accessioned | 2020-07-23T01:55:03Z | - |
dc.date.available | 2020-07-23T01:55:03Z | - |
dc.date.created | 2020-07-20 | - |
dc.date.created | 2020-07-20 | - |
dc.date.created | 2020-07-20 | - |
dc.date.issued | 2020-06 | - |
dc.identifier.citation | IMMUNE NETWORK, v.20, no.3 | - |
dc.identifier.issn | 1598-2629 | - |
dc.identifier.uri | http://hdl.handle.net/10203/275613 | - |
dc.description.abstract | Although various studies on predictive markers in the use of PD-1/PD-L1 inhibitors are in progress, only PD-L1 expression levels in tumor tissues are currently used. In the present study, we investigated whether baseline serum levels of IL-6 can predict the treatment response of patients with advanced non-small cell lung cancer (NSCLC) treated with PD-1/ PD-L1 inhibitors. In our cohort of 125 NSCLC patients, the objective response rate (ORR) and disease control rate (DCR) were significantly higher in those with low IL-6 (<13.1 pg/ml) than those with high IL-6 (ORR 33.9% vs. 11.1%, p=0.003; DCR 80.6% vs. 34.9%, p<0.001). The median progression-free survival was 6.3 months (95% confidence interval [CI], 3.9-8.7) in the low IL-6 group, significantly longer than in the high IL-6 group (1.9 months, 95% CI, 1.6-2.2, p<0.001). The median overall survival in the low IL-6 group was significantly longer than in the high IL-6 group (not reached vs. 7.4 months, 95% CI, 4.8-10.0). Thus, baseline serum IL-6 levels could be a potential biomarker for predicting the efficacy and survival benefit of PD-1/PD-L1 inhibitors in NSCLC. | - |
dc.language | English | - |
dc.publisher | KOREA ASSOC IMMUNOLOGISTS | - |
dc.title | Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1/PD-L1 Inhibitors | - |
dc.type | Article | - |
dc.identifier.wosid | 000546250100006 | - |
dc.identifier.scopusid | 2-s2.0-85087417436 | - |
dc.type.rims | ART | - |
dc.citation.volume | 20 | - |
dc.citation.issue | 3 | - |
dc.citation.publicationname | IMMUNE NETWORK | - |
dc.identifier.doi | 10.4110/in.2020.20.e27 | - |
dc.identifier.kciid | ART002606205 | - |
dc.contributor.localauthor | Shin, Eui-Cheol | - |
dc.contributor.nonIdAuthor | Kang, Da Hyun | - |
dc.contributor.nonIdAuthor | Park, Cheol-Kyu | - |
dc.contributor.nonIdAuthor | Chung, Chaeuk | - |
dc.contributor.nonIdAuthor | Oh, In-Jae | - |
dc.contributor.nonIdAuthor | Kim, Young-Chul | - |
dc.contributor.nonIdAuthor | Park, Dongil | - |
dc.contributor.nonIdAuthor | Kim, Jinhyun | - |
dc.contributor.nonIdAuthor | Kwon, Gye Cheol | - |
dc.contributor.nonIdAuthor | Kwon, Insun | - |
dc.contributor.nonIdAuthor | Sun, Pureum | - |
dc.contributor.nonIdAuthor | Lee, Jeong Eun | - |
dc.description.isOpenAccess | Y | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordAuthor | IL-6 | - |
dc.subject.keywordAuthor | Lung cancer | - |
dc.subject.keywordAuthor | Immunological antineoplastic agents | - |
dc.subject.keywordAuthor | PD-1/PD-L1 | - |
dc.subject.keywordPlus | TUMOR MUTATIONAL BURDEN | - |
dc.subject.keywordPlus | BIOMARKERS | - |
dc.subject.keywordPlus | DOCETAXEL | - |
dc.subject.keywordPlus | NIVOLUMAB | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | IL-6 | - |
dc.subject.keywordPlus | IMMUNOTHERAPY | - |
dc.subject.keywordPlus | BLOCKADE | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | STAT3 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.